Investment Overview - The company's investment amount for the 2024 reporting period was ¥509,010,836.54, a decrease of 23.12% compared to the previous year [1] - Future investment plans focus on "systematic, international, and intelligent" strategies to enhance business expansion and technological innovation [1] Financial Performance - In 2024, the company achieved a total revenue of ¥50.10 billion, with domestic revenue at ¥38.03 billion (75.90%) and international revenue at ¥12.07 billion (24.10%), reflecting an 11.19% decline year-on-year [4] - The net profit attributable to shareholders was ¥1.94 billion, down 67.66% from the previous year, while the net profit after deducting non-recurring gains and losses was ¥1.14 billion, a decrease of 79.39% [4] Strategic Goals for 2025 - Revenue growth is targeted through market expansion and a focus on high-value overseas business [3] - Cost control measures include supply chain optimization and the introduction of an intelligent approval system to reduce unnecessary expenses [3] - The company aims to enhance cash flow management and improve customer satisfaction to shorten accounts receivable turnover days [3] Technological Development - The company is committed to integrating artificial intelligence with pharmaceutical equipment to enhance product innovation and maintain a competitive edge [2] - Collaboration with Huawei on smart factory projects aims to drive the intelligent development of the pharmaceutical industry [4] Market Outlook - The pharmaceutical equipment industry is expected to benefit from government policies promoting innovation and the development of related industrial chains [7] - The aging population and increasing chronic disease prevalence are anticipated to drive sustained demand for pharmaceuticals, providing ongoing growth opportunities for the industry [7]